Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Posts 21 Percent Gain in Q2 Revenues

NEW YORK, July 29 (GenomeWeb News) - Lexicon Genetics today reported second quarter revenues of $10.8 million, up 21 percent from 2003 second quarter revenues of $8.9 million.


The Woodlands, Texas-based firm primarily attributed the increase in revenues to a collaborative neuroscience research pact with Bristol-Myers Squibb.


For the quarter ended June 30, 2004, Lexicon Genetics reported a net loss of $16.8 million, or $.26 per share, down from the net loss of $17.6 million, or $.34 per share, reported in the second quarter of 2003. The firm's research and development expenses grew to $22.6 million from $20.8 million in the comparable period a year ago.


At the end of the second quarter, Lexicon Genetics held cash and investments of $104.3 million, compared to $145.4 million at the end of its first quarter.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.